| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/01/2004 | EP1451552A2 Reagents and methods useful for detecting diseases of the breast |
| 09/01/2004 | EP1451369A2 Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201 |
| 09/01/2004 | EP1451368A2 Single nucleotide polymorphisms in gh-1 |
| 09/01/2004 | EP1451364A2 Methods and compositions for treating hematological disorders using 232, 2059, 10630, 12848, 13875, 14395, 14618, 17692 or 58874 |
| 09/01/2004 | EP1451363A2 Antisense modulation of thyroid hormone receptor interactor 6 expression |
| 09/01/2004 | EP1451353A2 Antisense modulation of phospholipase a2 group v expression |
| 09/01/2004 | EP1451337A2 Nogo receptor-mediated blockade of axonal growth |
| 09/01/2004 | EP1451333A2 Ul16 binding protein 4 |
| 09/01/2004 | EP1451329A2 Genetic vaccine against human immunodeficiency virus |
| 09/01/2004 | EP1451324A2 G-protein coupled receptor lustr2 and uses thereof |
| 09/01/2004 | EP1451323A2 Pharmaceutical compositions of marine sponge microciona prolifera |
| 09/01/2004 | EP1451322A2 Il-21 antagonists |
| 09/01/2004 | EP1451315A2 Human coagulation factor vii polypeptides |
| 09/01/2004 | EP1451312A2 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 09/01/2004 | EP1451307A2 Type 2 cytokine receptor and nucleic acids encoding same |
| 09/01/2004 | EP1451300A2 Methods and compositions for the use of stromal cells to support embryonic and adult stem cells |
| 09/01/2004 | EP1451294A2 Nutrient medium for maintaining neural cells in injured nervous system |
| 09/01/2004 | EP1451225A1 Agonists of recombinant human histamine h3 receptor |
| 09/01/2004 | EP1451222A2 Novel proteins with il-6 inhibiting activity |
| 09/01/2004 | EP1451221A2 GIPs, A FAMILY OF POLYPEPTIDES WITH TRANSCRIPTION FACTOR ACTIVITY THAT INTERACT WITH GOODPASTURE ANTIGEN BINDING PROTEIN |
| 09/01/2004 | EP1451219A1 Nuclear protein "shoca" - a component of the wnt signalling pathway |
| 09/01/2004 | EP1451218A2 Methods for the treatment and prognosis of leukemia and other cancer types |
| 09/01/2004 | EP1451214A2 Protein-protein interactions in human immunodeficiency virus |
| 09/01/2004 | EP1451213A2 Human and murine cytokine polypeptides |
| 09/01/2004 | EP1451212A2 Structural and cytoskeleton-associated proteins |
| 09/01/2004 | EP1451210A2 Hepta-, octa- and nonapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451209A2 Tetra-,penta-,hexa- and heptapeptides having antiangiogenic activity |
| 09/01/2004 | EP1451208A2 Concentrating aqueous fractions of lisinopril by reverse osmosis |
| 09/01/2004 | EP1451205A2 Antisense therapy using oligonucleotides that target human kinesin genes for treatment of cancer |
| 09/01/2004 | EP1451181A1 Dimeric compounds and their use as anti-viral agents |
| 09/01/2004 | EP1450872A1 Composition and method for treatment of wounds |
| 09/01/2004 | EP1450856A2 Packaging of immunostimulatory substances into virus-like particles: method of preparation and use |
| 09/01/2004 | EP1450855A2 Suppression of allergic reactions by transdermal administration of allergens in conjunction with or conjugated to toxin subunits or fragments thereof |
| 09/01/2004 | EP1450853A1 Lipoprotein lipase and lipoprotein lipase activators in the treatment of inflammatory conditions |
| 09/01/2004 | EP1450852A2 Ptp10d, tec and edtp involved in triglycerid-metabolism |
| 09/01/2004 | EP1450851A1 Treatment of congestive heart failure |
| 09/01/2004 | EP1450850A1 Method of administering a thymosin alpha 1 peptide |
| 09/01/2004 | EP1450849A2 Methods of treating endometreosis |
| 09/01/2004 | EP1450848A2 Methods of treating liver fibrosis and hepatitis c virus infection |
| 09/01/2004 | EP1450847A2 Apo2 ligand/trail formulations |
| 09/01/2004 | EP1450845A2 15603, a human ion channel family member |
| 09/01/2004 | EP1450843A2 Use of thymulin-like peptides for making pain-relieving medicines |
| 09/01/2004 | EP1450842A2 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof |
| 09/01/2004 | EP1450841A2 Tri-, tetra-, and penta-peptides having antiangiogenic activity |
| 09/01/2004 | EP1450840A2 Di-, tri,- and tetra-peptides having antiangiogenic activity |
| 09/01/2004 | EP1450839A2 Method of treating estrogen responsive breast cancer |
| 09/01/2004 | EP1450838A1 Method of treating hepatitis virus infection with a multiphasic interferon delivery profile |
| 09/01/2004 | EP1450837A2 Interleukin-1 receptors in the treatment of diseases |
| 09/01/2004 | EP1450836A2 Method for short-term and long-term drug dosimetry |
| 09/01/2004 | EP1450835A2 Compositions for the treatment of lupus, other rheumatic diseases and joint diseases |
| 09/01/2004 | EP1450831A2 Methods of treatment in situ in the lungs of mammals |
| 09/01/2004 | EP1450829A1 Storage-stable fibrinogen solutions |
| 09/01/2004 | EP1450828A2 In situ immunization |
| 09/01/2004 | EP1450821A1 Immunostimulatory oligodeoxynucleotides |
| 09/01/2004 | EP1450813A1 Antagonists of prostaglandin receptors ep2 and/or ep4 for the treatment of dysmenorrhea and menorrhagia |
| 09/01/2004 | EP1450809A2 Nucleosides preparation thereof and use as inhibitors of rna viral polymerases |
| 09/01/2004 | EP1450795A1 Peptide isosteres containing a heterocycle useful in the treatment of alzheimer's disease |
| 09/01/2004 | EP1450766A1 Prolonged release biodegradable microspheres and method for preparing same |
| 09/01/2004 | EP1450765A2 Sustained-release compositions |
| 09/01/2004 | EP1450762A1 Novel formulation |
| 09/01/2004 | EP1450752A2 Multivalent streptococcal vaccine compositions and methods for use |
| 09/01/2004 | EP1450751A2 Nanoparticle delivery vehicle |
| 09/01/2004 | EP1450629A1 Solid and stable creatine/citric acid composition(s) and compositions containing carbohydrate(s) or hydrates thereof, method for the production and use thereof |
| 09/01/2004 | EP1450605A2 A composition and method to alter lean body mass and bone properties in a subject |
| 09/01/2004 | EP1337228A4 Compositions for removing human cerumen |
| 09/01/2004 | EP1303534A4 Promyostatin peptides and methods of using same |
| 09/01/2004 | EP1220659B1 Pharmaceutical products and methods of fabrication therefor |
| 09/01/2004 | EP1218411A4 Secreted proteins and uses thereof |
| 09/01/2004 | EP1194138A4 Nutritional supplements |
| 09/01/2004 | EP1140851B1 4-oxo-1,4-dihydro-3-quinolinecarboxamides as antiviral agents |
| 09/01/2004 | EP1115738A4 Synthesis of cyclic peptides |
| 09/01/2004 | EP1089764B1 Stimulating the immune system |
| 09/01/2004 | EP1047769B1 Novel therapeutic uses of heterologous superoxide dismutase (hsd), and method for selecting said hsd |
| 09/01/2004 | EP1037529A4 Composition useful for providing one-step surgical preparation and drape |
| 09/01/2004 | EP1027067B1 Use of substances having oxytocin activity for the preparation of medicaments for the treatment of affective pain syndromes |
| 09/01/2004 | EP0975764B1 A gene delivery vehicle expressing the apoptosis-inducing proteins vp2 and/or apoptin |
| 09/01/2004 | EP0941369B1 Dna for evaluating the progression potential of cervical lesions |
| 09/01/2004 | EP0906336B1 Antibiotic producing microbe |
| 09/01/2004 | EP0834320B1 Albumin as active ingredient for treating corneal and conjunctival lesion and dry eye |
| 09/01/2004 | EP0831752B1 A device for delivering a preselected molecule into the systemic circulation |
| 09/01/2004 | EP0808630B1 Cancer control |
| 09/01/2004 | EP0772627B1 Production of biologically active recombinant neurotrophic protein |
| 09/01/2004 | EP0764172B1 Synthetic peptide analogs of lung surfactant protein sp-c |
| 09/01/2004 | EP0610254B1 Glial derived neurotrophic factor |
| 09/01/2004 | CN1526261A Mounting arrangement for auxiliary burner or lance |
| 09/01/2004 | CN1526111A Polymorphic marker that can be used to assess the efficacy of interferon therapy |
| 09/01/2004 | CN1526072A Method for the identification of extracellular domains of the epstein barr virus (ebv), tumor-associated latent membrane proteins and for the selection of antibody reagents reactive therewith |
| 09/01/2004 | CN1526020A Di- or oligomer of a dimer, trimer, quatrometer or pentamer of recombinant fusion proteins. |
| 09/01/2004 | CN1526018A Recombinant poxvirus for chimeric proteins of the human immunodeficiency virus |
| 09/01/2004 | CN1526014A Paramyxovirus vectors for introducing foreign genes into skeletal muscle |
| 09/01/2004 | CN1525980A Tumor antigen peptides originating in cyclophilin B |
| 09/01/2004 | CN1525979A Bridged bicyclic serine protease inhibitors |
| 09/01/2004 | CN1525978A C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases |
| 09/01/2004 | CN1525977A Purification of human serum albumin |
| 09/01/2004 | CN1525867A Pharmaceutically stable hemostatic compositions |
| 09/01/2004 | CN1525866A Treatment using neublastin polypeptides |
| 09/01/2004 | CN1525865A Use of lhrh-antagonists for the improvement of t-cell mediated immunity |
| 09/01/2004 | CN1525864A Mucin peptide with immunoenhancing properties |
| 09/01/2004 | CN1524958A Angiotensin II correlative gene, coding protein and application thereof |
| 09/01/2004 | CN1524950A Bacterial strain for preparing high efficiency capsule glycoprotein immunomodulator, screening and application thereof |